BioSpace News Archive

The rising prevalence of cognitive deficits and human malignancies in Alzheimer’s disease and Down Syndrome stands as a key factor aiding in expansion of the global dual specificity tyrosine phosphorylation regulated kinase 1A market during the forecast period, 2020 to 2030.

Initial data show that treatment with ruxolitinib plus standard-of-care (SoC) did not prevent complications in patients with COVID-19 associated cytokine storm

a SARS-CoV-2 RT-PCR test that has been successfully validated for pharynx gargling samples, providing a gold standard PCR test in an easy-to-use, self-sampling format especially beneficial in the testing of children.

New results from the Phase 2a STAMP-NAFLD trial show consistently greater response in high-risk patients with coexisting type 2 diabetes (T2DM), estimated to be approximately 50% of NASH patients

Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing revolutionary therapies for hard-to-drug targets, announced a collaboration with Tempus, a leader in artificial intelligence and precision medicine, to drive the development of Hummingbird’s lead clinical program, HMBD-001, as it advances into clinical trials in HER3-driven cancers, including those that harbor neuregulin 1 fusions.

Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced that it has been selected for addition to the NASDAQ Biotechnology Index (Nasdaq: NBI), effective prior to market open on Monday, December 21, 2020.

Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biopharmaceutical company creating a new class of drugs based on targeted protein degradation using its PROTAC® Discovery Engine, today announced clinical program updates for its PROTAC® protein degraders ARV-471 and ARV-110.

Updated dose-ranging data demonstrate potential for full normalization of FIX activity Long-term follow up data show durable FIX activity out to almost 3 years Completed End of Phase 2 Meeting with the U.S. FDA with expected initiation of pivotal Phase 2b/3 trial planned in H2 2021 Conference call today, 14 December, 8:30 AM ET

NurOwn® will be made available for ALS patients who completed all Phase 3 clinical trial assessments and meet specific eligibility criteria

Earlier this fall, the Company announced a joint working agreement to integrate a major manufacturer’s devices with its HealthTab™ data reporting platform for deployment in Canada, resulting in new testing capabilities, including COVID-19 molecular PCR results via the ID Now™.